Nom anglais: Polycystic Kidney, Autosomal Dominant
Descriptor UI:D016891
Tree Number:C16.320.184.625.500
Termes MeSH sélectionnés :
Drug Delivery Systems
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Polykystose rénale autosomique dominante : Questions médicales les plus fréquentes",
"headline": "Polykystose rénale autosomique dominante : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Polykystose rénale autosomique dominante : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-01",
"dateModified": "2025-03-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Polykystose rénale autosomique dominante"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Polykystoses rénales",
"url": "https://questionsmedicales.fr/mesh/D007690",
"about": {
"@type": "MedicalCondition",
"name": "Polykystoses rénales",
"code": {
"@type": "MedicalCode",
"code": "D007690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C16.320.184.625"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Polykystose rénale autosomique dominante",
"alternateName": "Polycystic Kidney, Autosomal Dominant",
"code": {
"@type": "MedicalCode",
"code": "D016891",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Vicente E Torres",
"url": "https://questionsmedicales.fr/author/Vicente%20E%20Torres",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Rochester, Minnesota, USA. Electronic address: Torres.vicente@mayo.edu."
}
},
{
"@type": "Person",
"name": "Peter C Harris",
"url": "https://questionsmedicales.fr/author/Peter%20C%20Harris",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN."
}
},
{
"@type": "Person",
"name": "Sarah R Senum",
"url": "https://questionsmedicales.fr/author/Sarah%20R%20Senum",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Ronald D Perrone",
"url": "https://questionsmedicales.fr/author/Ronald%20D%20Perrone",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA, USA. Electronic address: rperrone@tuftsmedicalcenter.org."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Dutch Pregnancy Drug Register: Suitable to Study Paternal Drug Exposures?",
"datePublished": "2023-11-24",
"url": "https://questionsmedicales.fr/article/38063537",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20237107"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Drug Utilization Study of Anti-glaucoma Drugs in a Tertiary Care Hospital.",
"datePublished": "2023-10-09",
"url": "https://questionsmedicales.fr/article/37954708",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.46765"
}
},
{
"@type": "ScholarlyArticle",
"name": "The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37503500",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.40983"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.",
"datePublished": "2023-04-28",
"url": "https://questionsmedicales.fr/article/37050863",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bcp.15743"
}
},
{
"@type": "ScholarlyArticle",
"name": "DDI-MuG: Multi-aspect graphs for drug-drug interaction extraction.",
"datePublished": "2023-04-24",
"url": "https://questionsmedicales.fr/article/37168529",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fdgth.2023.1154133"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Malformations et maladies congénitales, héréditaires et néonatales",
"item": "https://questionsmedicales.fr/mesh/D009358"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies génétiques congénitales",
"item": "https://questionsmedicales.fr/mesh/D030342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ciliopathies",
"item": "https://questionsmedicales.fr/mesh/D000072661"
},
{
"@type": "ListItem",
"position": 5,
"name": "Polykystoses rénales",
"item": "https://questionsmedicales.fr/mesh/D007690"
},
{
"@type": "ListItem",
"position": 6,
"name": "Polykystose rénale autosomique dominante",
"item": "https://questionsmedicales.fr/mesh/D016891"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Polykystose rénale autosomique dominante - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Polykystose rénale autosomique dominante",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Polykystose rénale autosomique dominante",
"description": "Comment diagnostiquer la polykystose rénale autosomique dominante ?\nQuels tests génétiques sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent cette maladie ?\nÀ quel âge se manifeste généralement la maladie ?\nL'échographie est-elle suffisante pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D016891?mesh_terms=Drug+Delivery+Systems&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Polykystose rénale autosomique dominante",
"description": "Quels sont les symptômes courants de la maladie ?\nLa polykystose rénale cause-t-elle des problèmes urinaires ?\nPeut-on avoir des symptômes sans kystes visibles ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLa fatigue est-elle un symptôme associé ?",
"url": "https://questionsmedicales.fr/mesh/D016891?mesh_terms=Drug+Delivery+Systems&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Polykystose rénale autosomique dominante",
"description": "Peut-on prévenir la polykystose rénale autosomique dominante ?\nComment surveiller la maladie chez les membres de la famille ?\nL'alimentation peut-elle influencer la maladie ?\nLe contrôle de la pression artérielle est-il important ?\nLes examens réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D016891?mesh_terms=Drug+Delivery+Systems&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Polykystose rénale autosomique dominante",
"description": "Quels traitements sont disponibles pour cette maladie ?\nLes médicaments peuvent-ils ralentir la progression ?\nLa dialyse est-elle nécessaire pour tous les patients ?\nY a-t-il des traitements expérimentaux disponibles ?\nComment gérer les douleurs associées à la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D016891?mesh_terms=Drug+Delivery+Systems&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Polykystose rénale autosomique dominante",
"description": "Quelles sont les complications possibles de la maladie ?\nLa polykystose rénale augmente-t-elle le risque de maladies cardiovasculaires ?\nLes kystes peuvent-ils se développer dans d'autres organes ?\nComment l'insuffisance rénale affecte-t-elle la qualité de vie ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D016891?mesh_terms=Drug+Delivery+Systems&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Polykystose rénale autosomique dominante",
"description": "Quels sont les facteurs de risque de la polykystose rénale ?\nL'âge influence-t-il le risque de développer la maladie ?\nLes hommes sont-ils plus à risque que les femmes ?\nLes personnes ayant des antécédents de maladies rénales sont-elles à risque ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D016891?mesh_terms=Drug+Delivery+Systems&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la polykystose rénale autosomique dominante ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, comme l'échographie ou l'IRM, et l'historique familial."
}
},
{
"@type": "Question",
"name": "Quels tests génétiques sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent identifier des mutations dans les gènes PKD1 ou PKD2."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent cette maladie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent hypertension, douleurs abdominales et hématurie."
}
},
{
"@type": "Question",
"name": "À quel âge se manifeste généralement la maladie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes apparaissent souvent entre 30 et 40 ans, mais peuvent survenir plus tôt."
}
},
{
"@type": "Question",
"name": "L'échographie est-elle suffisante pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'échographie est souvent suffisante pour visualiser les kystes rénaux."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la maladie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs lombaires, hypertension, et infections urinaires fréquentes."
}
},
{
"@type": "Question",
"name": "La polykystose rénale cause-t-elle des problèmes urinaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des infections urinaires et des calculs rénaux."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans kystes visibles ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent ne pas avoir de kystes visibles mais présenter des symptômes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme associé ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut être un symptôme en raison de l'insuffisance rénale progressive."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la polykystose rénale autosomique dominante ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La maladie étant génétique, il n'existe pas de prévention, mais un suivi régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Comment surveiller la maladie chez les membres de la famille ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échographies régulières et des consultations médicales sont recommandées pour les membres à risque."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle influencer la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et une bonne hydratation peuvent aider à maintenir la santé rénale."
}
},
{
"@type": "Question",
"name": "Le contrôle de la pression artérielle est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, maintenir une pression artérielle normale est crucial pour ralentir la progression de la maladie."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers permettent de détecter précocement des complications potentielles."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette maladie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut la gestion de l'hypertension et, dans les cas avancés, la dialyse ou la transplantation."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils ralentir la progression ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de l'angiotensine peuvent aider à contrôler la pression artérielle."
}
},
{
"@type": "Question",
"name": "La dialyse est-elle nécessaire pour tous les patients ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la dialyse est nécessaire uniquement lorsque la fonction rénale est gravement altérée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements expérimentaux, comme les médicaments ciblant la croissance des kystes, sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Comment gérer les douleurs associées à la maladie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analgésiques et des traitements non médicamenteux peuvent aider à gérer la douleur."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la maladie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale, les infections urinaires et les kystes hépatiques."
}
},
{
"@type": "Question",
"name": "La polykystose rénale augmente-t-elle le risque de maladies cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients ont un risque accru de maladies cardiovasculaires en raison de l'hypertension."
}
},
{
"@type": "Question",
"name": "Les kystes peuvent-ils se développer dans d'autres organes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des kystes peuvent également se former dans le foie, le pancréas et d'autres organes."
}
},
{
"@type": "Question",
"name": "Comment l'insuffisance rénale affecte-t-elle la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'insuffisance rénale peut entraîner fatigue, limitations physiques et besoin de dialyse, affectant la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un suivi médical régulier et un bon contrôle de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de la polykystose rénale ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de la maladie sont le principal facteur de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de développer la maladie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 30 ans."
}
},
{
"@type": "Question",
"name": "Les hommes sont-ils plus à risque que les femmes ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la polykystose rénale touche les hommes et les femmes de manière égale."
}
},
{
"@type": "Question",
"name": "Les personnes ayant des antécédents de maladies rénales sont-elles à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de maladies rénales peuvent augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de complications, mais pas le risque de la maladie elle-même."
}
}
]
}
]
}
Paternal medication use around the time of conception is common, but information about its effects on pregnancy outcome and the health of the child is generally limited. The aim of this study is to ex...
Today, branded medications and polytherapy are frequently prescribed for glaucoma, even without giving the patient the proper instructions. Hence, the safety, effectiveness, cost, and patient complian...
Between January 2021 and February 2022, this prospective and observational study was carried out at Andhra Medical College in Vishakhapatnam. One hundred prescriptions of those with primary open-angle...
Out of 146 examined prescriptions, 100 (69%) were deemed suitable for analysis. Participants' mean age was 54.2 ± 10.8 years. Sixty-two were over 50 years old, and 36 were men. The mean intraocular pr...
The most often prescribed anti-glaucoma drug, timolol, was also identified as an essential component of the FDC. Doctors must prescribe generic medications with detailed directions for the patients....
Xylazine is an alpha-adrenergic receptor agonist approved for use only in animals with a prescription from a veterinarian. It is a powerful sedative that is slowly infiltrating the recreational street...
Midostaurin is often prescribed with azole antifungals in patients with leukaemia, either for aspergillosis prophylaxis or treatment. Midostaurin is extensively metabolized by cytochrome (CYP) 3A4. In...
Drug-drug interaction (DDI) may lead to adverse reactions in patients, thus it is important to extract such knowledge from biomedical texts. However, previously proposed approaches typically focus on ...
We first employ a bio-specific pre-trained language model to obtain the token contextualized representations. Then we use two graphs to get syntactic information from input instance and word co-occurr...
To validate the effectiveness of the proposed model, we perform extensive experiments on two widely used DDI extraction dataset, DDIExtraction-2013 and TAC 2018. It is encouraging to see that our mode...
In contrast to the majority of earlier models that rely on the black-box approach, our model enables visualization of crucial words and their interrelationships by utilizing edge information from two ...
Receptor chromatography involves high-throughput separation and accurate drug screening based on specific drug-receptor recognition and affinity, which has been widely used to screen active compounds ...
Aging is an irreversible physiological process in the human body, and the aging characteristics of the body that accompany this process also lead to many other chronic diseases, such as neurodegenerat...
Antibiotic resistance has become a significant problem in typhoid fever due to the emergence of extensively drug resistant (XDR)...
A retrospective chart review was conducted at Liaquat National Hospital and Medical University, in Karachi, Pakistan. Patient records were identified from the microbiology laboratory data of all admit...
Out of 254 patients, 179 (70%) were male with an average age of 11.7 ± 10.9 years. Around 190 (74%) patients were treated with combination therapy, 126 (49%) were given azithromycin and meropenem and ...
Single antimicrobial therapy achieved defervescence earlier than combination therapy, with carbapenems performing better than azithromycin....
The dapivirine (DPV) vaginal ring was developed by the nonprofit International Partnership for Microbicides (IPM) for reducing the risk of HIV infection. A clinical study (IPM 028) showed that concomi...
Limited data exist on factors associated with concurrent use patterns of electronic nicotine delivery systems (ENDS) and cigarettes. We examined longitudinally perceptions and experiences with ENDS in...
Participant recruitment took place using paid digital advertisements on social media. Between December 2020 and October 2021, 303 adults aged ≥21 years from across the US who currently or recently smo...
At follow-up at 1 to 2 months after initiating ENDS, 20% were rejectors, 31% were primary smokers, 13% were dual users, 19% were primary vapers, and 17% were switchers/quitters. Perceiving ENDS as les...
Findings highlight the importance of initial ENDS perceptions and experiences when examining tobacco outcomes and potentially for developing policies and interventions targeting smoking cessation. END...